Diadema Partners LP Neurocrine Biosciences Inc Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Diadema Partners LP holds 94,042 shares of NBIX stock, worth $14.3 Million. This represents 3.6% of its overall portfolio holdings.
Number of Shares
94,042
Previous 62,247
51.08%
Holding current value
$14.3 Million
Previous $6.88 Billion
71.69%
% of portfolio
3.6%
Previous 1.8%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
697Shares Held
104MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.16 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.48 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$848 Million0.42% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$721 Million0.04% of portfolio
-
State Street Corp Boston, MA4.47MShares$681 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...